1-3 of 3
Kristen Schlueter
Close
Sort by
Journal Articles

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Sherry Fada, Michael Spector, Kathleen Stefunek, Heather Staley, Kristen Schlueter, Christy J. Samaras, Faiz Anwer, Jack Khouri, Jeffrey A. Zonder, Michaela Liedtke, Susan B. Sobolov
Journal: Blood
Blood (2021) 138 (Supplement 1): 2724.
https://doi.org/10.1182/blood-2021-148905
Published: 2021
Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5566.
https://doi.org/10.1182/blood-2019-129002
Published: 2019
Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3148.
https://doi.org/10.1182/blood-2019-131400
Published: 2019